TrialLancet (London, England)2014
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Kathleen M Dungan et al.PubMed ↗Publisher ↗
The primary results report of NCT01624259. Its numbers are set against the trial’s posted results below.
No numbers read from the abstract.
Against the trial’s posted results
- Same as the trial’s posted resultThis paper difference −0.06 (−0.19 to 0.07)Posted, primary outcome difference −0.06 (−0.19 to 0.07), p <0.001Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
220 papers cite itlatest 60 shown
this paperpooled ittrialcites it